Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Exploiting Transcriptional Adaptation to Develop New Genetic Compensation-based Therapies

Objective

Organisms display various mechanisms to compensate for the deleterious effects of harmful mutations. One such mechanism is transcriptional adaptation (TA), a recently identified mode of gene regulation whereby mutant mRNA decay triggers the transcriptional modulation of so-called adapting genes, independently of protein loss (Rossi et al., Nature 2015; El-Brolosy et al., Nature 2019). In some cases, TA can lead to functional compensation by upregulating genes that are functionally redundant with the mutated gene. In our funded project, Transcriptional Adaptation and Genetic Compensation (TAaGC), we are investigating the mechanisms underlying TA and its relevance to human health and disease. We have now observed TA in human cells and found that splice-switching antisense oligonucleotides (ASOs) can be used as tools to induce TA (Falcucci et al., Nature 2025). By causing the skipping of out-of-frame exons, these ASOs disrupt the reading frame, thereby triggering mutant mRNA decay and the upregulation of functional paralogs. Using this approach, we have induced the upregulation of functional paralogs for both the DMD and LMNA genes, mutations in which cause Duchenne muscular dystrophy and laminopathies, respectively. ASOs have been approved by regulatory agencies, including the FDA, for the treatment of multiple diseases, altogether suggesting that splice-switching ASOs constitute a viable therapeutic approach to induce functional compensation via TA. In this PoC project, we first aim to further optimize the sequence of TA-inducing ASOs for DMD and LMNA in human and mouse cells in culture. The optimized human ASOs will then be fully investigated in relevant human cells in regards to their effect on the transcriptome and proteome; the optimized mouse ASOs will be tested in wild-type and mutant mice. Together, these studies will identify lead ASO candidates ready for further preclinical and clinical development in the treatment of DMD and laminopathies.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
HOFGARTENSTRASSE 8
80539 MUNCHEN
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0